No Data
Reviva Pharm Holdings Initiated at Buy by EF Hutton
Express News | Reviva Pharmaceuticals Holdings, Inc. - Statistically Significant Vocal Biomarker Data Reinforce Efficacy of Brilaroxazine
Express News | Reviva Pharmaceuticals Holdings, Inc.: Additional Vocal Biomarker Data From Ongoing Open Label Extension Study Expected Q4 2024
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Maxim Group analyst Jason McCarthy maintains $Reviva Pharmaceuticals(RVPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 24.3% and a total average return of -22.
Maxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference